Authors
Latest:
CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple MyelomaPanelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.
Latest:
Face-Off: Award CeremonyFollowing a comprehensive debate on the treatment of patients with non–small cell lung cancer, Edward Kim, MD, presents the winning team with the title of victors of this CancerNetwork® Face-Off event.
Latest:
Pembrolizumab Combo Yields Efficacy in Penile Squamous Cell CarcinomaPembrolizumab plus platinum-containing therapy may be a new treatment option for advanced penile cancer based on data from the HERCULES trial.
Latest:
Empowering Awareness to Address Rising Gynecological Cancer IncidenceGinger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.
Latest:
Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell TumorIn this edition of Clinical Quandaries, Regina Barragan-Carrillo, MD, and colleagues present a case of an 18-year-old man who has a 1-month history of nonpainful right testicular enlargement.
Latest:
Highlighting Ongoing Clinical Trials in CML From ASHKendra Sweet, MD, discussed several ongoing studies in chronic myeloid leukemia, with some initial results presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
Latest:
Improving the Management of HNSCC: Next StepsDr Cesar Perez reacts to the utilization of next-generation sequencing in head and neck squamous cell carcinoma and highlights future areas of study.
Latest:
Unusual Clinical Presentation of Clear Cell Sarcoma in a Young WomanA young woman presents with painless lumps to the emergency department and is later diagnosed with clear cell carcinoma.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
Educating Patients and Caregivers on Infection Risks of Anti-BCMA Bispecific Antibodies in MM TreatmentThe panel discusses how to educate patients and caregivers on infections risks when receiving an anti-BCMA bispecific antibody.
Latest:
Key Takeaways: Optimal Use of JAK Inhibitors in MF and Future Directions in CarePanelists share key takeaways on management strategies in myelofibrosis and hope for future evolutions in the treatment paradigm.
Latest:
Value of Collaboration in Managing Patients With Metastatic RCCClosing out their discussion on the management of metastatic renal cell carcinoma, panelists highlight the value of collaborative care in improving patient outcomes.
Latest:
Michael Szarek, PhD, on Research Areas of Focus for Tivozanib in RCCThe expert from SUNY Downstate Medical Center spoke about areas of research for renal cell carcinoma which he believes deserve further attention.
Latest:
Oncology On-The-Go Podcast: SGO 2023 RecapExperts from UCLA Health discuss key data presented at The Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer and how they may apply to clinical practice.
Latest:
Looking Forward: Advice for Clinicians and Discussing Unmet Needs in the R/R MM LandscapeDr. Joshua Richter and Dr. Peter Forsberg close their discission with thoughtful advice for clinicians regarding the current and future treatment of patients with R/R MM.
Latest:
Exploring CAR-T Therapy in Early Lines of Relapsed/Refractory Multiple MyelomaPanelists discuss the data surrounding the use of CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM), including findings from the cilta-cel (Popat R, et al. ASH 2024 No. 1032; Mateos MV, et al. IMS 2024 No. OA-65), and Idel-cel (Ailawadhi S, et al. Blood 2024) studies, and share their thoughts on the implications of these results.
Latest:
Face-Off: Award Presentation CeremonyFollowing a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.
Latest:
Dostarlimab/Chemo Yields “Unprecedented” OS in dMMR Endometrial CancerDostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Latest:
Oncology Peer Review On-The-Go: Routine Breast Cancer Screening in Average-Risk Women Younger Than 50 YearsCancerNetwork’s latest podcast episode features a conversation with Anath Ravi, PhD, of MOLLI Surgical and Randy Miles, MD, MPH, of Massachusetts General Hospital on the risks and benefits of breast cancer screening for average-risk women under the age of 50 years.
Latest:
Making Intervention Accessible for All Li-Fraumeni Syndrome PopulationsMichael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
